PCM
GANX icon

Potomac Capital Management’s Gain Therapeutics GANX Stock Holding History

Potomac Capital Management’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.96M Sell
1,008,600
-1,400
-0.1% -$3.05K 1.7% 15
2025
Q4 		$3.25M Buy
+1,010,000
New +$2.7M 2.61% 11

Other funds holding GANX

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Potomac Capital Management's GANX Position: Q1 2026 in Review

Potomac Capital Management reduced its Gain Therapeutics (GANX) stake by 0.14% in Q1 2026, selling an estimated $3.05K and leaving 1,008,600 shares worth $1.96M. The position accounts for 1.7% of the portfolio, ranked #15.

Potomac Capital Management first reported a position in GANX in Q4 2025 and has held it in 2 quarters since. The position peaked at $3.25M in Q4 2025. 42 funds tracked by Wall St. Rank hold GANX as of Q1 2026.

  • Potomac Capital Management held 1,008,600 shares of Gain Therapeutics worth $1.96M as of Q1 2026.
  • Potomac Capital Management sold 1,400 Gain Therapeutics shares in Q1 2026, an estimated $3.05K.
  • Gain Therapeutics made up 1.7% of Potomac Capital Management's portfolio in Q1 2026, its #15 holding.
  • Potomac Capital Management first reported a position in Gain Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Potomac Capital Management's Gain Therapeutics position peaked at $3.25M in Q4 2025.
  • 42 funds tracked by Wall St. Rank held Gain Therapeutics as of Q1 2026.

Based on Potomac Capital Management's 13F filing for Q1 2026, filed 14 May 2026.